Valisure’s Co-Founder & President, David Light, was invited to speak at the Industry Studies Association (ISA) Webinar titled “Improving the Safety, Security, Robustness, and Resilience of the Nation’s Drug Supply Chain,” held on October 6.

The webinar brought together leaders from across healthcare, policy, and manufacturing to discuss findings from the U.S. Department of Health and Human Services’ supply chain review, released in June 2021 as part of the Biden Administration’s broader assessment of critical infrastructure. The review identified key vulnerabilities in the pharmaceutical supply chain and called for a system that is geographically diversified, quality-driven, redundant, and adaptable to fluctuations in demand.

David Light joined a distinguished panel of experts, offering insights from Valisure’s work in independent batch-level chemical testing and the company’s growing role in identifying quality lapses that contribute to supply chain fragility.

Webinar Panel Participants:

• Moderator: John Gray, Professor, Fisher College of Business, Ohio State University
• Presenter: Elisabeth Reynolds, Special Assistant to the President, National Economic Council
• Panelists:
  • Dr. Harry Lever, Cardiologist, Cleveland Clinic
  • David Light, Co-Founder & President, Valisure
  • Eric Edwards, President & CEO, Phlow

The session provided a comprehensive look at the pharmaceutical supply chain—from active pharmaceutical ingredients (APIs) to clinical delivery—and highlighted actionable strategies to improve national preparedness and public health resilience.

‍

Valisure’s Co-Founder & President, David Light, was invited to speak at the Industry Studies Association (ISA) Webinar titled “Improving the Safety, Security, Robustness, and Resilience of the Nation’s Drug Supply Chain,” held on October 6.

The webinar brought together leaders from across healthcare, policy, and manufacturing to discuss findings from the U.S. Department of Health and Human Services’ supply chain review, released in June 2021 as part of the Biden Administration’s broader assessment of critical infrastructure. The review identified key vulnerabilities in the pharmaceutical supply chain and called for a system that is geographically diversified, quality-driven, redundant, and adaptable to fluctuations in demand.

David Light joined a distinguished panel of experts, offering insights from Valisure’s work in independent batch-level chemical testing and the company’s growing role in identifying quality lapses that contribute to supply chain fragility.

Webinar Panel Participants:

• Moderator: John Gray, Professor, Fisher College of Business, Ohio State University
• Presenter: Elisabeth Reynolds, Special Assistant to the President, National Economic Council
• Panelists:
  • Dr. Harry Lever, Cardiologist, Cleveland Clinic
  • David Light, Co-Founder & President, Valisure
  • Eric Edwards, President & CEO, Phlow

The session provided a comprehensive look at the pharmaceutical supply chain—from active pharmaceutical ingredients (APIs) to clinical delivery—and highlighted actionable strategies to improve national preparedness and public health resilience.

‍